{"id":"W2944795532","doi":"10.1158/1538-7445.sabcs18-ot3-04-03","title":"Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Anthracycline; Chemotherapy; Pembrolizumab; Neoadjuvant therapy; Cancer; Placebo; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002547876,0.00236473,0.003954885,0.0005281199,0.0006509881,0.001478429,0.001425728,0.002691705,0.01083304],"category_scores_gemma":[0.002051049,0.0008430266,0.002805045,0.000574252,0.001435271,0.001247325,0.0004853267,0.003793362,0.001529896],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001073476,"about_ca_system_score_gemma":0.001969552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001788497,"about_ca_topic_score_gemma":0.003727546,"domain_scores_codex":[0.9991301,0.0004386851,0.0000614468,0.0001891475,0.00006428831,0.0001163183],"domain_scores_gemma":[0.9989756,0.000236652,0.0002721418,0.00008821932,0.0000968231,0.0003305451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9831109,0.005827094,0.0001477787,0.0008706411,0.001162161,0.00001444534,0.00001692501,0.000133635,0.002257562,0.00006637624,0.0007004253,0.005692085],"study_design_scores_gemma":[0.9741255,0.02439136,0.0003672015,0.00002582578,0.0004953151,0.000008696754,0.000007920304,0.0001304302,0.0001678672,0.00004368661,0.0002286558,0.000007502749],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9549686,0.01455686,0.002055922,0.001667977,0.002428498,0.01529453,0.004335758,0.0005775978,0.00411419],"genre_scores_gemma":[0.9624383,0.005353353,0.004105874,0.003492673,0.001015346,0.01486503,0.002423244,0.00006783161,0.006238295],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01083304,"threshold_uncertainty_score":0.0362401,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03599447944760348,"score_gpt":0.376260371835144,"score_spread":0.3402658923875406,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}